Published in J Virol on August 01, 1986
Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J Virol (1991) 3.62
Differential effects of mutations in three domains on folding, quaternary structure, and intracellular transport of vesicular stomatitis virus G protein. J Cell Biol (1988) 3.10
Recognition of similar epitopes on varicella-zoster virus gpI and gpIV by monoclonal antibodies. J Virol (1988) 0.91
Intracellular processing and transport of NH2-terminally truncated forms of a hemagglutinin-neuraminidase type II glycoprotein. J Cell Biol (1990) 0.83
Overexpression of human virus surface glycoprotein precursors induces cytosolic unfolded protein response in Saccharomyces cerevisiae. Microb Cell Fact (2011) 0.82
Identification of mumps virus protein and lipid composition by mass spectrometry. Virol J (2016) 0.76
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Intracellular aspects of the process of protein synthesis. Science (1975) 25.21
Synthesis and processing of asparagine-linked oligosaccharides. Annu Rev Biochem (1981) 11.44
Mechanisms for the incorporation of proteins in membranes and organelles. J Cell Biol (1982) 9.67
The golgi apparatus: two organelles in tandem. Science (1981) 4.15
Mutants of vesicular stomatitis virus blocked at different stages in maturation of the viral glycoprotein. Cell (1980) 3.65
Compartmentation of asparagine-linked oligosaccharide processing in the Golgi apparatus. J Cell Biol (1983) 2.65
Impaired intracellular migration and altered solubility of nonglycosylated glycoproteins of vesicular stomatitis virus and Sindbis virus. J Biol Chem (1977) 2.36
Synthesis and infectivity of vesicular stomatitis virus containing nonglycosylated G protein. Cell (1978) 2.23
Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization. J Cell Biol (1984) 2.13
Using recombinant DNA techniques to study protein targeting in the eucaryotic cell. Annu Rev Cell Biol (1985) 2.07
Sequence determination of the Sendai virus HN gene and its comparison to the influenza virus glycoproteins. Cell (1985) 2.01
Glucose removal from N-linked oligosaccharides is required for efficient maturation of certain secretory glycoproteins from the rough endoplasmic reticulum to the Golgi complex. J Cell Biol (1984) 1.97
Vesicular stomatitis virus glycoprotein, albumin, and transferrin are transported to the cell surface via the same Golgi vesicles. J Cell Biol (1983) 1.94
Hemagglutinin-neuraminidase protein of the paramyxovirus simian virus 5: nucleotide sequence of the mRNA predicts an N-terminal membrane anchor. J Virol (1985) 1.87
Identification of the P proteins and other disulfide-linked and phosphorylated proteins of Newcastle disease virus. J Virol (1981) 1.41
The carboxyterminus of the hemagglutinin-neuraminidase of Newcastle disease virus is exposed at the surface of the viral envelope. Virus Res (1984) 1.31
Conversion of nonfusing mumps virus infections to fusing infections by selective proteolysis of the HN glycoprotein. Virology (1983) 1.28
Co-translational excision of alpha-glucose and alpha-mannose in nascent vesicular stomatitis virus G protein. J Cell Biol (1984) 1.28
Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis. J Virol (1985) 1.23
Carbohydrate-induced conformational changes of Semliki forest virus glycoproteins determine antigenicity. Virology (1980) 1.16
Maturation of the envelope glycoproteins of Newcastle disease virus on cellular membranes. J Virol (1982) 1.15
Processing of the asparagine-linked oligosaccharides of secreted and intracellular forms of the vesicular stomatitis virus G protein: in vivo evidence of Golgi apparatus compartmentalization. J Cell Biol (1985) 1.01
Differentiation of mumps virus strains with monoclonal antibody to the HN glycoprotein. Infect Immun (1982) 0.98
Proteolytic activation of the haemagglutinin-neuraminidase of Newcastle disease virus involves loss of a glycopeptide. J Gen Virol (1980) 0.94
Biosynthesis of mumps virus F glycoprotein: non-fusing strains efficiently cleave the F glycoprotein precursor. J Gen Virol (1983) 0.88
Posttranslational modification and intracellular transport of mumps virus glycoproteins. J Virol (1983) 0.79
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Importance of antibodies to the fusion glycoprotein of paramyxoviruses in the prevention of spread of infection. J Exp Med (1980) 3.32
In situ hybridization histochemistry of Ca2+/calmodulin-dependent protein kinase in developing rat brain. J Neurosci (1990) 3.00
Slow virus replication: the role of macrophages in the persistence and expression of visna viruses of sheep and goats. J Gen Virol (1982) 2.87
An essential role for postsynaptic calmodulin and protein kinase activity in long-term potentiation. Nature (1989) 2.83
Immunological studies of the functions of paramyxovirus glycoproteins. Virology (1981) 1.93
Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imaging. AJNR Am J Neuroradiol (2007) 1.83
H reflex studies in cerebral palsy patients undergoing partial dorsal rhizotomy. Muscle Nerve (1994) 1.83
Sequence similarities between human immunodeficiency virus gp41 and paramyxovirus fusion proteins. AIDS Res Hum Retroviruses (1987) 1.82
Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol (2006) 1.78
In vitro synthesis of structural and nonstructural proteins of Sendai and SV5 viruses. Virology (1980) 1.78
Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology (2001) 1.76
Three-dimensional reconstructions of calcium/calmodulin-dependent (CaM) kinase IIalpha and truncated CaM kinase IIalpha reveal a unique organization for its structural core and functional domains. J Biol Chem (2000) 1.70
Herpes zoster ophthalmicus and delayed contralateral hemiparesis caused by cerebral angiitis: diagnosis and management approaches. Ann Neurol (1983) 1.60
Variable results after rituximab in neuromyelitis optica. J Neurol Sci (2012) 1.58
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology (2000) 1.52
Measles encephalomyelitis--clinical and immunologic studies. N Engl J Med (1984) 1.50
The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology (2009) 1.49
Copolymer 1: a most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability. Neurology (1995) 1.48
Immunochemical identification of rubella virus hemagglutinin. Virology (1983) 1.44
Acquired toxoplasmosis. A neglected cause of treatable nervous system disease. Arch Neurol (1975) 1.44
Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis. Arch Neurol (2001) 1.40
3D MPRAGE improves classification of cortical lesions in multiple sclerosis. Mult Scler (2008) 1.39
A peptide model for calmodulin trapping by calcium/calmodulin-dependent protein kinase II. J Biol Chem (1996) 1.38
The relationship of MS to physical trauma and psychological stress: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (1999) 1.38
Sequence determination of the mumps virus HN gene. Virology (1988) 1.38
Effects of seasons on magnetic resonance imaging--measured disease activity in patients with multiple sclerosis. Ann Neurol (2001) 1.35
Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand (2010) 1.34
DCC and netrins. Curr Opin Cell Biol (1998) 1.33
Regulation of the UNC-5 netrin receptor initiates the first reorientation of migrating distal tip cells in Caenorhabditis elegans. Development (2000) 1.31
Neutralizing antibody spectrum determines the antigenic profiles of emerging mutants of visna virus. Infect Immun (1981) 1.31
The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology (1999) 1.31
Primary culture of capillary endothelium from rat brain. In Vitro (1981) 1.30
Ca(2+)/calmodulin-dependent protein kinases. Cell Mol Life Sci (2008) 1.30
MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology (2006) 1.29
Progressive rubella panencephalitis. Late onset after congenital rubella. N Engl J Med (1975) 1.28
Conversion of nonfusing mumps virus infections to fusing infections by selective proteolysis of the HN glycoprotein. Virology (1983) 1.28
Biochemical features of mumps virus neuraminidases and their relationship with pathogenicity. Virology (1981) 1.27
Detailed immunologic analysis of the structural polypeptides of rubella virus using monoclonal antibodies. Virology (1985) 1.26
Neuronal and oligodendroglial infection by the WW strain of Theiler's virus. Lab Invest (1979) 1.25
A dual approach for minimizing false lesion classifications on magnetic resonance images. Magn Reson Med (1997) 1.24
Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis. J Virol (1985) 1.23
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler (2000) 1.23
Cloning and sequencing of the mumps virus fusion protein gene. Virology (1987) 1.20
A fusing mumps virus variant selected from a nonfusing parent with the neuraminidase inhibitor 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology (1986) 1.18
Virus-specific intracytoplasmic inclusions in mouse brain produced by a newly isolated strain of Theiler virus. I. Virologic and morphologic studies. Lab Invest (1977) 1.18
Isolation of metabolically active capillaries from rat brain. J Neurochem (1975) 1.15
A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler (2006) 1.15
Determinants of overall quality of life in secondary progressive MS: a longitudinal study. Neurology (2001) 1.13
Postinfectious leukoencephalitis complicating Mycoplasma pneumoniae infection. Arch Neurol (1983) 1.12
Neuronal activity increases the phosphorylation of the transcription factor cAMP response element-binding protein (CREB) in rat hippocampus and cortex. J Biol Chem (1996) 1.11
Interactions of FLT-1 and KDR with phospholipase C gamma: identification of the phosphotyrosine binding sites. Biochem Biophys Res Commun (1997) 1.11
Inhibition of the neuraminidase of paramyxoviruses by halide ions: a possible means of modulating the two activities of the HN protein. Virology (1981) 1.10
Adenine arabinoside in the treatment of progressive multifocal leukoencephalopathy: use of virus-containing cells in the urine to assess response to therapy. Ann Neurol (1977) 1.10
Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology (2004) 1.09
Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain (2001) 1.08
Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol (1998) 1.08
Identification of domains essential for the assembly of calcium/calmodulin-dependent protein kinase II holoenzymes. J Biol Chem (1998) 1.06
Skeletal muscle CaMKII enriches in nuclei and phosphorylates myogenic factor SRF at multiple sites. Biochem Biophys Res Commun (2000) 1.05
Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial. Neurology (2012) 1.05
Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol (1998) 1.04
Prognosis of the individual course of disease--steps in developing a decision support tool for Multiple Sclerosis. BMC Med Inform Decis Mak (2007) 1.04
Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Mult Scler (2008) 1.04
Ultrastructure of mumps virus replication in newborn hamster central nervous system. Lab Invest (1974) 1.04
The neuropathology of progressive rubella panencephalitis of late onset. Brain (1976) 1.04
Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Neurology (1996) 1.04
Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of phosphatidylinositol 3-kinase. Mapping of a novel site involved in binding. J Biol Chem (1995) 1.03
Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging. Mult Scler (2001) 1.02
The functions and inhibition of the membrane glycoproteins of paramyxoviruses and myxoviruses and the role of the measles virus M protein in subacute sclerosing panencephalitis. J Infect Dis (1981) 1.02
Characterization of immune complexes in progressive rubella panencephalitis. Ann Neurol (1981) 1.02
A model of the structural organization of rubella virions. Rev Infect Dis (1985) 1.01
Ischemia-induced translocation of Ca2+/calmodulin-dependent protein kinase II: potential role in neuronal damage. J Neurochem (1992) 0.99
Inactivation and self-association of Ca2+/calmodulin-dependent protein kinase II during autophosphorylation. J Biol Chem (1996) 0.99
Virulence and persistence of three prototype strains of mumps virus in newborn hamsters. Arch Virol (1978) 0.98
Differentiation of mumps virus strains with monoclonal antibody to the HN glycoprotein. Infect Immun (1982) 0.98
Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol (1998) 0.98
EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. Eur J Neurol (2006) 0.97
Composite MRI scores improve correlation with EDSS in multiple sclerosis. Mult Scler (2010) 0.96
Varicella-zoster virus infection of human brain cells and ganglion cells in tissue culture. Arch Virol (1978) 0.96
Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand (2005) 0.96
Active site-directed inhibition of Ca2+/calmodulin-dependent protein kinase type II by a bifunctional calmodulin-binding peptide. Proc Natl Acad Sci U S A (1988) 0.95
Progressive rubella panencephalitis. Arch Neurol (1976) 0.95
Activation of the alternative complement pathway by mumps infected cells: relationship to viral neuraminidase activity. Arch Virol (1986) 0.94
Diagnostic tests in normal pressure hydrocephalus. Neurology (1973) 0.93
Light scattering and transmission electron microscopy studies reveal a mechanism for calcium/calmodulin-dependent protein kinase II self-association. J Neurochem (2001) 0.93
Rubella-specific immune complexes after congenital infection and vaccination. Infect Immun (1982) 0.93